A new report from Kaufman Hall examines two potential financial situations for hospitals in 2021 one optimistic, and the other bleak. Hospitals could lose between $53 billion and $122 billion depending on which scenario plays out.
MedCity News
FDA approves Sarepta drug for muscular dystrophy with rare genetic mutation
The FDA decision gives Sarepta Therapeutics its third approved drug for Duchenne muscular dystrophy. The accelerated approval requires the biotech to conduct additional clinical testing to confirm the drug’s benefit.
Shares0
The FDA has approved a Sarepta Therapeutics drug for Duchenne muscular dystrophy, clearing the way for the company to commercialize its third therapy for the rare, muscle-wasting disease.
Thursday’s decision covers patients with a particular genetic mutation that affects an estimated 8% of Duchenne patients. The drug, casimersen, will be marketed under the name Amondys 45.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Slovenski left his perch atop Walmart Health last year to join a diagnostics company that has been around since 2005. In our latest podcast episode, he talks about the future of the diagnostics industry and his ambitions for a wholesale reinvention.
MedCity News
More healthcare startups go public through SPACs but will they succeed?
More healthcare startups are choosing to go public through mergers with special-purpose acquisition companies publicly-traded shell companies created with the purpose of taking a private company public. But as the number of SPACs searching for targets increases, will the SPAC bubble burst?
Shares1
From the beginning, Hims & Hers CEO Andrew Dudum had imagined he would take his startup public through a traditional IPO. But last month, the direct-to-consumer health startup ended up taking a different route.
The startup merged with a special-purpose acquisition company formed by Oaktree Capital Management, effectively a shell company that goes public with the purpose of finding and acquiring a target company. The deal netted Hims & Hers a $1.6 billion valuation and $330 million in cash.